FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors

#3361

Introduction: Well-differentiated neuroendocrine tumors (NETs) are relatively rare, highly vascularized neoplasms. Antiangiogenic drugs have shown efficacy in patients with advanced NETs. Bevacizumab is a well-known antiangiogenic monoclonal antibody.

Aim(s): To report the efficacy and tolerance of the FOLFOX-bevacizumab combination.

Materials and methods: We retrospectively studied patients with metastatic well-differentiated NETs treated by FOLFOX-bevacizumab, in two expert centers, from 2013 to 2020. Primary endpoint was time to treatment failure (TTF), and secondary endpoints were objective response (OR) rate and toxicity.

Conference:

Presenting Author:

Authors: Lacombe C, Perrier M, Hentic O, Brixi H, Rebours V,

Keywords: neuroendocrine tumor, antiangiogenic therapy, VEGF, well-differentiated,